Merck & Co., Inc. Overview
MRK market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
MRK price chart · 1M
- O
- 142.82
- H
- 147.13
- L
- 142.82
- C
- 146.76
- Vol
- 78,822.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $142.82
- Previous Close
- $146.89
- Day High
- $147.13
- Day Low
- $142.82
- 52 Week High
- $155.98
- 52 Week Low
- $82.06
- 7 Day Return
- -1.86%
- 30 Day Return
- +2.82%
- 90 Day Return
- +12.78%
- 1 Year Return
- +76.07%
- Daily Notional Volume
- $11.6M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 151.23 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $7.28 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 3.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $82.01 – $156.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $371B · P/B 4.97 · P/S 5.51.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Moderna Just Gave Investors Yet Another Thing to Cheer AboutThe Motley Fool ·
Mexico Animal Healthcare Market Size and Share Analysis - Industry Trends and Growth Forecasts (2026-2031) | Diagnostics and Pet Care Fuel Growth to USD 3.34 BillionGlobenewswire Inc ·
Merck Deepens Strategic Partnership with JD Health to Expand Access to Innovative Medicines in ChinaFiscal.ai ·
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.The Motley Fool ·
History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492The Motley Fool ·
Merck Updates 2026 Financial GuidanceFiscal.ai ·